PMID- 31122538
OWN - NLM
STAT- MEDLINE
DCOM- 20191224
LR  - 20191224
IS  - 1875-6263 (Electronic)
IS  - 1028-4559 (Linking)
VI  - 58
IP  - 3
DP  - 2019 May
TI  - Could serum levels of irisin be used in gestational diabetes predicting?
PG  - 434-437
LID - S1028-4559(19)30060-9 [pii]
LID - 10.1016/j.tjog.2019.01.027 [doi]
AB  - OBJECTIVE: Gestational diabetes mellitus (GDM) is a metabolic disorder during 
      pregnancy leading to acute and chronic complications in both mother and newborn. 
      The pathogenesis of GDM has not been fully understood, However, since the disease 
      shares risk factors with type 2 diabetes mellitus (T2DM), a relationship between 
      these two disease states is plausible. The recently discovered peptide irisin has 
      been hypothesized to be a regulator of body metabolism. However, studies ended up 
      with controversial results. In the present study, we aimed to investigate the 
      relationship between irisin levels and gestational diabetes mellitus and the 
      possible benefits of the metabolic profile. MATERIALS AND METHODS: We performed a 
      cross-sectional analysis of circulating levels of irisin in 100 pregnant women 
      similar for age and body mass index and the groups included 50 gestational 
      diabetic patients and 50 healthy pregnant volunteers. Serum irisin levels were 
      measured by ELISA kit. RESULTS: Mean age and body mass index levels were similar 
      in both groups. Median HbA1c, fasting blood glucose, Glucose 1 h, Glucose 2 h and 
      fasting insulin levels were higher in with gestational diabetic patients compared 
      to the control group. In gestational diabetic group, the median irisin level was 
      lower than in the control group. CONCLUSION: Serum irisin levels were lower in 
      gestational diabetic patients. Further investigations are needed to explore the 
      underlying biological effects of irisin on pregnant women.
CI  - Copyright (c) 2019. Published by Elsevier B.V.
FAU - Kulhan, Nur Gozde
AU  - Kulhan NG
AD  - Erzincan University Medical Faculty, Gynaecology and Obstetrics Department, 
      Erzincan, Turkey.
FAU - Kulhan, Mehmet
AU  - Kulhan M
AD  - Erzincan University Medical Faculty, Gynaecology and Obstetrics Department, 
      Erzincan, Turkey. Electronic address: Mehmet_kulhan@yahoo.com.
FAU - Turkler, Can
AU  - Turkler C
AD  - Erzincan University Medical Faculty, Gynaecology and Obstetrics Department, 
      Erzincan, Turkey.
FAU - Ata, Nahit
AU  - Ata N
AD  - Erzincan University Medical Faculty, Gynaecology and Obstetrics Department, 
      Erzincan, Turkey.
FAU - Kiremitli, Tunay
AU  - Kiremitli T
AD  - Erzincan University Medical Faculty, Gynaecology and Obstetrics Department, 
      Erzincan, Turkey.
FAU - Kiremitli, Sevil
AU  - Kiremitli S
AD  - Erzincan University Medical Faculty, Gynaecology and Obstetrics Department, 
      Erzincan, Turkey.
LA  - eng
PT  - Journal Article
PL  - China (Republic : 1949- )
TA  - Taiwan J Obstet Gynecol
JT  - Taiwanese journal of obstetrics & gynecology
JID - 101213819
RN  - 0 (FNDC5 protein, human)
RN  - 0 (Fibronectins)
SB  - IM
CIN - Taiwan J Obstet Gynecol. 2019 Jul;58(4):443-444. PMID: 31307729
MH  - Adult
MH  - Case-Control Studies
MH  - Cross-Sectional Studies
MH  - Diabetes, Gestational/*blood/diagnosis
MH  - Female
MH  - Fibronectins/*blood
MH  - Humans
MH  - Pregnancy
MH  - Young Adult
OTO - NOTNLM
OT  - Gestational diabetes
OT  - Glucose intolerance
OT  - Hyperinsulinemia
OT  - Irisin
OT  - Maternal insulin resistance
EDAT- 2019/05/28 06:00
MHDA- 2019/12/25 06:00
CRDT- 2019/05/25 06:00
PHST- 2019/01/26 00:00 [accepted]
PHST- 2019/05/25 06:00 [entrez]
PHST- 2019/05/28 06:00 [pubmed]
PHST- 2019/12/25 06:00 [medline]
AID - S1028-4559(19)30060-9 [pii]
AID - 10.1016/j.tjog.2019.01.027 [doi]
PST - ppublish
SO  - Taiwan J Obstet Gynecol. 2019 May;58(3):434-437. doi: 10.1016/j.tjog.2019.01.027.